2018 Q1 Form 10-Q Financial Statement
#000156459018012976 Filed on May 10, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q4 | 2017 Q1 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $161.0K |
| YoY Change | -100.0% | -100.0% | -98.7% |
| Cost Of Revenue | $0.00 | ||
| YoY Change | |||
| Gross Profit | $0.00 | ||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $16.58M | $15.00M | $18.80M |
| YoY Change | -11.82% | -1.96% | 64.91% |
| % of Gross Profit | |||
| Research & Development | $25.46M | $31.50M | $53.78M |
| YoY Change | -52.66% | -46.61% | -17.65% |
| % of Gross Profit | |||
| Depreciation & Amortization | $900.0K | $900.0K | $900.0K |
| YoY Change | 0.0% | 12.5% | 28.57% |
| % of Gross Profit | |||
| Operating Expenses | $42.03M | $46.47M | $72.58M |
| YoY Change | -42.09% | -37.47% | -5.39% |
| Operating Profit | -$42.03M | -$72.42M | |
| YoY Change | -41.96% | 12.53% | |
| Interest Expense | $2.408M | -$2.400M | $2.376M |
| YoY Change | 1.35% | 0.0% | 183.87% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $138.0K | -$200.0K | -$29.00K |
| YoY Change | -575.86% | 100.0% | -91.69% |
| Pretax Income | -$44.30M | -$49.10M | -$74.80M |
| YoY Change | -40.78% | -35.31% | 14.2% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$44.30M | -$49.07M | -$74.78M |
| YoY Change | -40.76% | -35.37% | 14.36% |
| Net Earnings / Revenue | -46445.96% | ||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$737.1K | -$840.8K | -$1.536M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 51.15M | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q4 | 2017 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $95.20M | $126.9M | $174.8M |
| YoY Change | -45.54% | 1.6% | -2.67% |
| Cash & Equivalents | $82.02M | $126.9M | $124.9M |
| Short-Term Investments | $13.10M | $49.90M | |
| Other Short-Term Assets | $17.10M | $142.0K | $33.40M |
| YoY Change | -48.8% | -95.24% | 8.44% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $112.2M | $145.5M | $208.3M |
| YoY Change | -46.14% | -9.92% | -1.56% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $11.90M | $12.77M | $14.90M |
| YoY Change | -20.13% | 18.27% | 44.66% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $800.0K | $800.0K | $800.0K |
| YoY Change | 0.0% | -57.42% | 0.0% |
| Total Long-Term Assets | $16.30M | $17.12M | $19.20M |
| YoY Change | -15.1% | 0.81% | 31.51% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $112.2M | $145.5M | $208.3M |
| Total Long-Term Assets | $16.30M | $17.12M | $19.20M |
| Total Assets | $128.5M | $162.6M | $227.5M |
| YoY Change | -43.52% | -8.9% | 0.57% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $14.30M | $15.50M | $12.60M |
| YoY Change | 13.49% | -21.34% | -29.61% |
| Accrued Expenses | $9.400M | $6.976M | $22.80M |
| YoY Change | -58.77% | -75.11% | 18.13% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $27.62M | $28.40M | $47.30M |
| YoY Change | -41.6% | -49.65% | -49.09% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $102.0M | $101.6M | $100.6M |
| YoY Change | 1.39% | 1.3% | 1.31% |
| Other Long-Term Liabilities | $1.960M | $2.073M | $2.700M |
| YoY Change | -27.41% | -17.08% | -97.32% |
| Total Long-Term Liabilities | $1.960M | $2.073M | $103.3M |
| YoY Change | -98.1% | -97.98% | -48.4% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $27.62M | $28.40M | $47.30M |
| Total Long-Term Liabilities | $1.960M | $2.073M | $103.3M |
| Total Liabilities | $131.6M | $132.1M | $149.3M |
| YoY Change | -11.89% | -16.41% | -48.9% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$775.5M | ||
| YoY Change | |||
| Common Stock | $818.8M | $808.1M | |
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$1.800M | $30.54M | $78.20M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $128.5M | $162.6M | $227.5M |
| YoY Change | -43.53% | -8.9% | 0.57% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q4 | 2017 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$44.30M | -$49.07M | -$74.78M |
| YoY Change | -40.76% | -35.37% | 14.36% |
| Depreciation, Depletion And Amortization | $900.0K | $900.0K | $900.0K |
| YoY Change | 0.0% | 12.5% | 28.57% |
| Cash From Operating Activities | -$33.58M | -$29.90M | -$73.30M |
| YoY Change | -54.18% | -65.55% | -3.93% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $81.00K | -$100.0K | $1.691M |
| YoY Change | -95.21% | -97.22% | -21.28% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$13.10M | $14.50M | -$49.90M |
| YoY Change | -73.75% | ||
| Cash From Investing Activities | -$13.18M | $14.40M | -$51.60M |
| YoY Change | -74.46% | -500.0% | 2357.14% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 1.878M | 6.900M | 125.0M |
| YoY Change | -98.5% | -87.68% | 25.25% |
| NET CHANGE | |||
| Cash From Operating Activities | -33.58M | -29.90M | -73.30M |
| Cash From Investing Activities | -13.18M | 14.40M | -51.60M |
| Cash From Financing Activities | 1.878M | 6.900M | 125.0M |
| Net Change In Cash | -44.90M | -8.600M | -23.00K |
| YoY Change | 195117.39% | -75.0% | -100.11% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$33.58M | -$29.90M | -$73.30M |
| Capital Expenditures | $81.00K | -$100.0K | $1.691M |
| Free Cash Flow | -$33.67M | -$29.80M | -$74.99M |
| YoY Change | -55.11% | -64.18% | -4.41% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q1 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
3498000 | |
| CY2017Q1 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
161000 | |
| CY2018Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
25455000 | |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
53775000 | |
| CY2018Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
16577000 | |
| CY2017Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
18803000 | |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
42032000 | |
| CY2017Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
72578000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-42032000 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-72417000 | |
| CY2018Q1 | chrs |
Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
|
14206000 | |
| CY2018Q1 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
2789000 | |
| CY2017Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
3395000 | |
| CY2017Q4 | chrs |
Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
|
14969000 | |
| CY2018Q1 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
76474000 | |
| CY2018Q1 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
25492000 | |
| CY2018Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1960000 | |
| CY2018Q1 | us-gaap |
Liabilities
Liabilities
|
131550000 | |
| CY2018Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
128462000 | |
| CY2018Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
818753000 | |
| CY2018Q1 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
0 | |
| CY2018Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2018Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2018Q1 | us-gaap |
Minority Interest
MinorityInterest
|
-1294000 | |
| CY2018Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-3088000 | |
| CY2018Q1 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
0 | |
| CY2017Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-750000 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-775492000 | |
| CY2017Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
3290000 | |
| CY2018Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
367000 | |
| CY2018Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
27624000 | |
| CY2017Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
76206000 | |
| CY2017Q4 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
25402000 | |
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
2073000 | |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
132076000 | |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
808060000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
31824000 | |
| CY2017Q4 | us-gaap |
Minority Interest
MinorityInterest
|
-1289000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
30535000 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
162611000 | |
| CY2017Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
908000 | |
| CY2017Q4 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
510000 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
60122050 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-74778000 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.74 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.54 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
48711958 | |
| CY2018Q1 | us-gaap |
Interest Expense
InterestExpense
|
2408000 | |
| CY2017Q1 | us-gaap |
Interest Expense
InterestExpense
|
2376000 | |
| CY2018Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
138000 | |
| CY2017Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-29000 | |
| CY2018Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-44302000 | |
| CY2017Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-74822000 | |
| CY2018Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-5000 | |
| CY2017Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-44000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-44297000 | |
| CY2018Q1 | us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
34000 | |
| CY2017Q1 | us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
65000 | |
| CY2018Q1 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
602000 | |
| CY2017Q1 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
593000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-1000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-9000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-13000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-168000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-44316000 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-74999000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
-5000 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
-44000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-44311000 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-74955000 | |
| CY2018Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
922000 | |
| CY2017Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
865000 | |
| CY2018Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
208000 | |
| CY2017Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
390000 | |
| CY2018Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
44000 | |
| CY2017Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
19000 | |
| CY2018Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
358000 | |
| CY2017Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
326000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8720000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7810000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-1833000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-763000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
923000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-606000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-2076000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-109000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-118000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1068000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-7265000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
-199000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
1232000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
456000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-4831000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-168000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-113000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
101000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-73277000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
81000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1691000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-33584000 | |
| CY2018Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-44900000 | |
| CY2017Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-23000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
127756000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
125792000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
13100000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
49887000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-13181000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-51578000 | |
| CY2018Q1 | chrs |
Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts And Commissions
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsAndCommissions
|
1781000 | |
| CY2017Q1 | chrs |
Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts And Commissions
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsAndCommissions
|
124866000 | |
| CY2018Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
128000 | |
| CY2017Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
134000 | |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
225000 | |
| CY2017Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
265000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
1878000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
124997000 | |
| CY2018Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-13000 | |
| CY2017Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-165000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82856000 | |
| CY2017Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
125769000 | |
| CY2018Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization and Operations<font style="font-weight:normal;"> </font></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coherus BioSciences, Inc. (the “Company”, “Coherus”, “we”, our” or “us”) is a late-stage clinical biologics platform company, focused on the global biosimilar market. The Company’s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Need to Raise Additional Capital<font style="font-weight:normal;"> </font></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2018, the Company had an accumulated deficit of $819.8 million and cash and cash equivalents and short-term investments in marketable securities of $95.2 million. In the first quarter of 2018, the Company issued and sold 192,642 shares of common stock at a weighted average price of $9.53 per share through its ATM Offering Program and received total net proceeds of $1.8 million (see Note 8). The Company believes that its current available cash and cash equivalents and short-term investments in marketable securities will be sufficient to fund its planned expenditures and meet the Company’s obligations <font style="color:#000000;">for at least 12 months following our financial statement issuance date</font><font style="color:#1F497D;">. </font>The Company will need to raise additional funds in the future; however, there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. If the Company is unable to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, research and development programs or commercialization efforts.</p></div> | |
| CY2017Q1 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
60000 | |
| CY2017Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
785000 | |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
18379251 | |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
15141953 | |
| CY2018Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, valuation of deferred tax assets, impairment of goodwill and long-lived assets, the valuation of acquired intangible assets, clinical trial accruals, revenue recognition period, contingent consideration, convertible notes valuation, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates. </p></div> | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
95200000 | |
| CY2018Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-8000 | |
| CY2017Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
171000 | |
| CY2018Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
124924000 | |
| CY2018Q1 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2018Q1 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
|
0 | |
| CY2017 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
|
0 | |
| CY2018Q1 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
|
0 | |
| CY2017 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
|
0 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
|
82000 | |
| CY2018Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
4027000 | |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2074000 | |
| CY2018Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1379000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1004000 | |
| CY2017Q2 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
1400000 | |
| CY2017Q2 | us-gaap |
Restructuring Charges
RestructuringCharges
|
3600000 | |
| CY2018Q1 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
2100000 | |
| CY2018Q1 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
0 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
|
46000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
|
0 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
|
19000 | |
| CY2018Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
22583000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
22575000 | |
| CY2018Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
10724000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
9802000 | |
| CY2018Q1 | chrs |
Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
|
3988000 | |
| CY2017Q4 | chrs |
Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
|
5462000 |
